BRIEF-Knight Therapeutics says received Notice Of Deficiency for its ATryn new drug submission

Mon Apr 25, 2016 8:13am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

April 25 (Reuters) - Knight Therapeutics Inc

* Has received a notice of deficiency for its ATryn new drug submission

* Health Canada requested additional technical information on ATryn in order to complete its assessment of product Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)